1. Targeting PI3-kinase ( PI3 K), AKT and m TOR axis in lymphoma.
- Author
-
Blachly, James S. and Baiocchi, Robert A.
- Subjects
- *
ONCOLOGY , *PHOSPHATIDYLINOSITOL 3-kinases , *RAPAMYCIN , *LYMPHOCYTES , *CELLULAR signal transduction , *CLINICAL trials , *PROTEIN expression - Abstract
Targeted therapy represents a transformation in oncology, a field that has relied primarily on non-selective cytotoxic therapies. Phosphatidylinositol 3-kinase ( PI3 K) is a family of ubiquitous signalling molecules involved in a wide variety of cellular processes and likewise, in a broad selection of human cancers. The discovery that the p110-δ form of PI3 K is differentially expressed in normal and malignant lymphocytes has led to the development of specific inhibitors that are currently in clinical trials for lymphoma. Downstream effectors of PI3 K, including v-akt murine thymoma viral oncogene homolog 1 ( AKT; also termed AKT1) and mechanistic target of rapamycin (serine/threonine kinase) (m TOR) are similarly important in lymphoma, and agents targeting these components of the PI3 K- AKT-m TOR axis are also underway, although at earlier stages of development. In this review we examine the role of PI3 K- AKT-m TOR in normal and malignant lymphocytes, as well as the preclinical and clinical status of a number of inhibitors of this pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF